AAD House Call: ARQ-151 for Chronic Plaque Psoriasis

Article

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

Late-breaking data originally planned for presentation the American Academy of Dermatology (AAD) 2020 Scientific Sessions—which has since been cancelled due to concerns raised by the coronavirus (COVID-19) pandemic—show greater potential for investigational drug ARQ-151 (roflumilast cream) as a treatment for chronic plaque psoriasis.

The phase 2b findings, gathered by Linda Stein Gold, MD, of the Henry Ford Hospital, and colleagues, compliment a growing portfolio for the PDE4 inhibitor as a potential treatment for inflammation-based, chronic skin diseases.

In a special edition House Call video interview with HCPLive®, Stein Gold discussed the new findings and what future benefit the topical therapy may have for dermatology.

Related Videos
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.